These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1116 related items for PubMed ID: 21680574

  • 21. Circulating tumor cells with a putative stem cell phenotype in peripheral blood of patients with breast cancer.
    Theodoropoulos PA, Polioudaki H, Agelaki S, Kallergi G, Saridaki Z, Mavroudis D, Georgoulias V.
    Cancer Lett; 2010 Feb 01; 288(1):99-106. PubMed ID: 19619935
    [Abstract] [Full Text] [Related]

  • 22. Semi-quantitative evaluation of CD44(+) /CD24(-) tumor cell distribution in breast cancer tissue using a newly developed fluorescence immunohistochemical staining method.
    Kai M, Onishi H, Souzaki M, Tanaka H, Kubo M, Tanaka M, Katano M.
    Cancer Sci; 2011 Dec 01; 102(12):2132-8. PubMed ID: 21838786
    [Abstract] [Full Text] [Related]

  • 23. Breast cancer stem cells and intrinsic subtypes: controversies rage on.
    Nakshatri H, Srour EF, Badve S.
    Curr Stem Cell Res Ther; 2009 Jan 01; 4(1):50-60. PubMed ID: 19149630
    [Abstract] [Full Text] [Related]

  • 24. Combination of Cancer Stem Cell Markers CD44 and CD24 Is Superior to ALDH1 as a Prognostic Indicator in Breast Cancer Patients with Distant Metastases.
    Horimoto Y, Arakawa A, Sasahara N, Tanabe M, Sai S, Himuro T, Saito M.
    PLoS One; 2016 Jan 01; 11(10):e0165253. PubMed ID: 27768764
    [Abstract] [Full Text] [Related]

  • 25. MicroRNA-9 is associated with epithelial-mesenchymal transition, breast cancer stem cell phenotype, and tumor progression in breast cancer.
    Gwak JM, Kim HJ, Kim EJ, Chung YR, Yun S, Seo AN, Lee HJ, Park SY.
    Breast Cancer Res Treat; 2014 Aug 01; 147(1):39-49. PubMed ID: 25086633
    [Abstract] [Full Text] [Related]

  • 26. Clinical implications of CD44+/CD24- tumor cell ratio in breast cancer.
    Liu C, Luo Y, Liu X, Lu P, Zhao Z.
    Cancer Biother Radiopharm; 2012 Jun 01; 27(5):324-8. PubMed ID: 22702496
    [Abstract] [Full Text] [Related]

  • 27. A novel mouse model of human breast cancer stem-like cells with high CD44+CD24-/lower phenotype metastasis to human bone.
    Ling LJ, Wang S, Liu XA, Shen EC, Ding Q, Lu C, Xu J, Cao QH, Zhu HQ, Wang F.
    Chin Med J (Engl); 2008 Oct 20; 121(20):1980-6. PubMed ID: 19080260
    [Abstract] [Full Text] [Related]

  • 28. Unraveling the roles of CD44/CD24 and ALDH1 as cancer stem cell markers in tumorigenesis and metastasis.
    Li W, Ma H, Zhang J, Zhu L, Wang C, Yang Y.
    Sci Rep; 2017 Oct 23; 7(1):13856. PubMed ID: 29062075
    [Abstract] [Full Text] [Related]

  • 29. Epithelial-mesenchymal transition increases during the progression of in situ to invasive basal-like breast cancer.
    Choi Y, Lee HJ, Jang MH, Gwak JM, Lee KS, Kim EJ, Kim HJ, Lee HE, Park SY.
    Hum Pathol; 2013 Nov 23; 44(11):2581-9. PubMed ID: 24055090
    [Abstract] [Full Text] [Related]

  • 30. Dynamic emergence of the mesenchymal CD44(pos)CD24(neg/low) phenotype in HER2-gene amplified breast cancer cells with de novo resistance to trastuzumab (Herceptin).
    Oliveras-Ferraros C, Vazquez-Martin A, Martin-Castillo B, Cufí S, Del Barco S, Lopez-Bonet E, Brunet J, Menendez JA.
    Biochem Biophys Res Commun; 2010 Jun 18; 397(1):27-33. PubMed ID: 20470755
    [Abstract] [Full Text] [Related]

  • 31. The expression pattern of aldehyde dehydrogenase 1 (ALDH1) is an independent prognostic marker for low survival in colorectal tumors.
    Vogler T, Kriegl L, Horst D, Engel J, Sagebiel S, Schäffauer AJ, Kirchner T, Jung A.
    Exp Mol Pathol; 2012 Feb 18; 92(1):111-7. PubMed ID: 22101256
    [Abstract] [Full Text] [Related]

  • 32. Clinical-pathologic significance of cancer stem cell marker expression in familial breast cancers.
    Bane A, Viloria-Petit A, Pinnaduwage D, Mulligan AM, O'Malley FP, Andrulis IL.
    Breast Cancer Res Treat; 2013 Jul 18; 140(1):195-205. PubMed ID: 23813303
    [Abstract] [Full Text] [Related]

  • 33. Immunohistochemical analysis of cancer stem cell markers in invasive breast carcinoma and associated ductal carcinoma in situ: relationships with markers of tumor hypoxia and microvascularity.
    Currie MJ, Beardsley BE, Harris GC, Gunningham SP, Dachs GU, Dijkstra B, Morrin HR, Wells JE, Robinson BA.
    Hum Pathol; 2013 Mar 18; 44(3):402-11. PubMed ID: 23036368
    [Abstract] [Full Text] [Related]

  • 34. ALDH1 is a better clinical indicator for relapse of invasive ductal breast cancer than the CD44+/CD24- phenotype.
    Zhong Y, Shen S, Zhou Y, Mao F, Guan J, Lin Y, Xu Y, Sun Q.
    Med Oncol; 2014 Mar 18; 31(3):864. PubMed ID: 24519209
    [Abstract] [Full Text] [Related]

  • 35. Aldehyde dehydrogenase 1 expression predicts poor prognosis in triple-negative breast cancer.
    Ohi Y, Umekita Y, Yoshioka T, Souda M, Rai Y, Sagara Y, Sagara Y, Sagara Y, Tanimoto A.
    Histopathology; 2011 Oct 18; 59(4):776-80. PubMed ID: 22014057
    [Abstract] [Full Text] [Related]

  • 36. Cancer stem cell markers ALDH1 and CD44+/CD24- phenotype and their prognosis impact in invasive ductal carcinoma.
    Rabinovich I, Sebastião APM, Lima RS, Urban CA, Junior ES, Anselmi KF, Elifio-Esposito S, De Noronha L, Moreno-Amaral AN.
    Eur J Histochem; 2018 Sep 03; 62(3):. PubMed ID: 30362671
    [Abstract] [Full Text] [Related]

  • 37. Expression of cancer stem cell markers in basal and penta-negative breast carcinomas--a study of a series of triple-negative tumors.
    Uchôa Dde M, Graudenz MS, Callegari-Jacques SM, Hartmann CR, Ferreira BP, Fitarelli-Kiehl M, Edelweiss MI.
    Pathol Res Pract; 2014 Jul 03; 210(7):432-9. PubMed ID: 24726267
    [Abstract] [Full Text] [Related]

  • 38. Are CD44+/CD24- cells the assumed cancer stem cells in breast cancer?
    Ryspayeva DE, Smolanka II, Dudnichenko АS, Lyashenko AA, Grinevich YA, Gurianov VG, Koshubarova MV, Seleznev AA.
    Exp Oncol; 2017 Sep 03; 39(3):224-228. PubMed ID: 28967636
    [Abstract] [Full Text] [Related]

  • 39. Immunohistochemical features of claudin-low intrinsic subtype in metaplastic breast carcinomas.
    Gerhard R, Ricardo S, Albergaria A, Gomes M, Silva AR, Logullo ÂF, Cameselle-Teijeiro JF, Paredes J, Schmitt F.
    Breast; 2012 Jun 03; 21(3):354-60. PubMed ID: 22464177
    [Abstract] [Full Text] [Related]

  • 40. Characterization of CD44+ALDH1+Ki-67- Cells in Non-malignant and Neoplastic Lesions of the Breast.
    DA Cruz Paula A, Marques O, Sampaio R, Rosa A, Garcia J, Rêma A, DE Fátima Faria M, Silva P, Vizcaíno R, Lopes C.
    Anticancer Res; 2016 Sep 03; 36(9):4629-38. PubMed ID: 27630305
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 56.